Actively Recruiting
Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders
Led by Charite University, Berlin, Germany · Updated on 2025-02-24
77
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A rater-blinded randomized controlled trial with a parallel-group design is utilized, comprised of yoga-based group intervention (YoGI) in the experimental condition, and treatment as usual (TAU) in the control condition. The participants in the experimental condition participate in YoGI beside their regular psychiatric treatment (TAU). The intervention is designed for in-patients with schizophrenia spectrum disorders. With the aim of examining the feasibility, acceptability and effectiveness, self-report and blinded rater-based assessments are evaluated before the YoGI (T0), and after four weeks of taking part in intervention (T1). Building on the results of the feasibility and acceptability trial, the study is now progressing to a full randomized controlled trial. The primary outcome for the full trial will be positive symptoms of schizophrenia spectrum disorders, assessed by a blinded rater using the Positive and Negative Syndrome Scale (PANSS). The target sample size has been adjusted to ensure sufficient statistical power, and the trial will evaluate secondary outcomes, including (body) mindfulness, negative symptoms, cognitive functioning, and quality of life, and stress. This study aims to provide robust evidence for the effectiveness of YoGI in comparison to treatment as usual (TAU).
CONDITIONS
Official Title
Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female participants
- Treated as psychiatric inpatients at the psychosis ward or in the social-psychiatric day clinic
- 18 years of age or older
- Diagnosis of schizophrenia-spectrum disorder according to DSM-5 and ICD-10 code F2
- Ability to give informed consent
- Willingness and ability to engage in psychotherapeutic group therapy
- Low to moderate psychotic state with scores of 6 or less on each item of the Positive scale of the PANSS
You will not qualify if you...
- Score greater than 6 indicating an acute psychotic episode with severe symptoms
- Acute suicidality with a score higher than 1 on item eight of the Calgary Depression Scale for Schizophrenia
- Any neurological disorders affecting cognitive functioning
- Acute substance abuse other than nicotine and prescribed medication
- Conflicting co-therapy such as electroconvulsive therapy or ketamine treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Steglitz, State of Berlin, Germany, 1220
Actively Recruiting
Research Team
K
Kerem Böge, Dr.
CONTACT
E
Eric Hahn, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here